Skip to main content

Table 4 Univariate and Multivariable Logistical Regression Analysis of Risk Factors for Pazopanib-Induced Hypertension

From: Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development

  Univariate analysis Multivariable analysis
  OR P-value OR P-value
Age ≥ 60 years 0.81 0.767   
Male (vs. female) 1.31 0.694   
Baseline SBP ≥ 130 mmHg 5.32 0.058 4.62 0.197
Antihypertensive therapy at baseline
ACEIs or ARBs 4.88 0.044 4.31 0.075
Calcium channel blockers 3.5 0.160   
Diuretics 2.17 0.400   
Beta-blockers 0.5 0.348   
≥ 2 Antihypertensives 4 0.078   
Baseline CV Risk Factors
Diabetes 1.23 0.767   
GFR < 60 ml/min/1.73m2 0.81 0.767   
BMI > 30 kg/m2 0.76 0.694   
Smokera 2.12 0.281   
Oncologic Profile
Prior Nephrectomy 0.75 0.687   
Pazopanib starting dose 800 mg 0.64 0.724   
  1. OR odds ratio, SBP systolic blood pressure, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker, CV cardiovascular, GFR glomerular filtration rate, BMI body mass index, ECOG Eastern Cooperative Oncology Group performance status
  2. aCurrent of past smoker